Company / R&D Expense
Ovid Therapeutics Inc. R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$36.8M
FY2025
5-year range
$24.6M / $46.9M
FY2022-FY2025
Trend
+28.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $25M to $37M over the past 2 years.
Based on SEC 10-K filings.
$37M in FY2025 with a 3-year CAGR of -7.8%.
Improved from $25M to $37M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -7.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -7.8%, indicating a declining trend.
- In FY2025, r&d expense increased 28.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.8M | +28.6% |
| FY2024 | $28.6M | +16.1% |
| FY2023 | $24.6M | -47.6% |
| FY2022 | $46.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026